HCM
SLS icon

Highbridge Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Highbridge Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$1.19K – 347
2024
Q2 		$1.19K Buy
+1,000
New +$1.36K ﹤0.01% 326

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Highbridge Capital Management's SLS Position: Q2 2026 in Review

Highbridge Capital Management opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 99,400 shares worth $1.47M. The stake represents 0.04% of the portfolio and ranks #198 among its holdings. This is a return to the name: Highbridge Capital Management previously reported a position in SLS as recently as Q3 2022.

Highbridge Capital Management first reported a position in SLS in Q2 2022 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Highbridge Capital Management held 99,400 shares of SELLAS Life Sciences worth $1.47M as of Q2 2026.
  • SELLAS Life Sciences was a new Highbridge Capital Management position in Q2 2026.
  • SELLAS Life Sciences made up 0.04% of Highbridge Capital Management's portfolio in Q2 2026, its #198 holding.
  • Highbridge Capital Management first reported a position in SELLAS Life Sciences in Q2 2022 and has held it in 3 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.